Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 98, Issue 3, 2004, Pages 301-310

  Migliorati, Cesar Augusto ^a   Birman, Esther Goldenberg ^b   Cury, Arlete Emily ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; FLUCONAZOLE; FLUCYTOSINE; IMIDAZOLE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASSAY; CANDIDA; CANDIDA CAPITATUM; CANDIDA FAMATA; CANDIDA GLABRATA; CANDIDA TROPICALIS; CANDIDIASIS; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG POTENTIATION; ENZYME RELEASE; FEMALE; FUNGUS CULTURE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MOUTH FLORA; OROPHARYNX CANDIDIASIS; STATISTICAL ANALYSIS; THRUSH;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIFUNGAL AGENTS; ASPARTIC ENDOPEPTIDASES; CANDIDA; CANDIDIASIS, ORAL; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RITONAVIR;

EID: 4444317560     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2004.05.017     Document Type: Article

References (43)

1. Silverman S. Jr., Migliorati C.A., Lozada-Nur F., Greenspan D., Conant M.A. Oral findings in people with or at risk for AIDS: a study of 375 homosexual males. J Am Dent Assoc. 112:1986;187-192
2. Dull J.S., Sem P., Rafanti S., Middleton J.R. Oral candidiasis as a marker of acute retrovirus illness. South Med J. 84:1991;733-735
3. Dios P.D., Ocampo A., Miralles C., Otero I., Iglesias I., Rayo N. Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 87:1999;437-441
4. Dios P.D., Ocampo A., Miralles C., Limeres J., Tomas I. Changing prevalence of human immunodeficiency virus-associated oral lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 90:2000;403-404
5. Deeks S.G., Smith M., Holodniy M., Kahn J.O. HIV-1 protease inhibitors. A review for clinicians. JAMA. 277:1997;145-153
6. Patton L.L., Mckaig R., Strauss R., Rogers D., Eron J.J. Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 89:2000;299-304
7. Powderly W.G., Landay A., Lederman M.M. Recovery of the immune system with antiretroviral therapy. The end of opportunism? JAMA. 280:1998;72-77
8. Sepkowitz K.A. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet. 351:1998;228-230
9. Hoegl L., Thoma-Greber E., Rocken M., Korting H.C. HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2 year study. Mycoses. 41:1998;321-325
10. Borg-von Zepelin M., Meyer I., Thomssem R., et al. HIV-Protease inhibitors reduce cell adherence of Candida albicans isolates by inhibition of yeast secreted aspartic proteases. J Invest Dermatol. 113:1999;747-751
11. Cassone A., De Bernardis F., Torosantucci A., Tacconelli E., Tumbarello M., Cauda R. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis. 180:1999;448-453
12. Cauda R., Tacconelli E., Tumbarello M., et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr. 21:1999;20-25
13. Gruber A., Speth C., Lukasser-Vogl E., et al. R. Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. J Immunopharmacol. 41:1999;227-234
14. Korting H.C., Schaller M., Eder G., Hamm G., Bohmer U., Hube B. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother. 43:1999;2038-2042
15. Monod M., Borg-von Zepelin M., Telenti A., Sanglard D. The inhibition of Candida albicans secreted aspartic proteases by three different HIV protease inhibitors. Dermatology. 198:1999;412-414
16. EC Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus. Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med. 22:1993;289-291
17. Migliorati C.A., Migliorati E.K.J. Oral lesions and HIV: an approach to the diagnosis of oral mucosal lesions for the dentist in private practice. Schweiz Monatsschr Zahnmed. 107:1997;861-868
18. Jones A.C., Pink R., Sandow P., Stewart C.M., Migliorati C.A., Baughman R. The Cytobrush Plus cell collector in oral cytology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 77:1994;101-104
19. Silverman S. Jr., Migliorati C.A., Epstein J.B., Samaranayake L.P. Laboratory diagnosis of oral candidosis. Samaranayake L.P., Macfarlane T.W. Oral candidosis. 1990;213-237 Wright, London
20. Lacaz C.S., Porto E., Martins J.E.C. Micologia médica. 8th ed. :1991;Sarvier, São Paulo
21. Kreger-Van Rij N.J.W. The yeast: a taxonomic study. 3rd ed. :1984;Elsevier, Amsterdam
22. Rüchel R., Tegeler R., Trost M.A. A comparison of secretory proteinases from different isolates of Candida albicans. Sabouraudia. 20:1982;233-244
23. Odds F.C., Bernaerts R. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol. 32:1994;1923-1929
24. National Committee for Clinical Laboratory Standards. Reference method for broth dilutions antifungal susceptibility testing of yeast: approved standard. NCCLS Document M27-A. 1997;Wayne, Pa
25. Price M.F., Wilkinson I.A., Gentry L.O. Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia. 20:1982;7-14
26. Silveira F.R.X., Birman E.G., Paula C.R., Batista J.M. Proteinase and phospholipase activity of Candida albicans isolated from oral mucosa of healthy carriers (smokers and nonsmokers). Rev Iber Micol. 10:1993;105-108
27. Rex J.H., Pfaller M.A., Galgiani J.N., et al. Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and Candida infection. Clin Infect Dis. 24:1997;235-247
28. Murray P.R. Manual of clinical microbiology. 1999;American Society of Microbiology, Washington (DC). p. 1640-52
29. Cury A.E. Testes de suscetibilidade in vitro com antifúngicos. [correction]:1995;Faculdade de Ciências Farmacêuticas-USP, São Paulo. p. 27
30. Greenspan D. Treatment of oral candidiasis in HIV infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 78:1994;211-215
31. Sant'Ana P de L., Milan E.P., Martinez R., et al. Multicenter Brazilian study of oral Candida species isolated from AIDS patients. Mem Inst Oswaldo Cruz. 97:2002;253-257
32. Barchiesi F., Morbidutcci V., Ancarani F., Scalise G. Emergence of oropharyngeal candidiasis caused by non albicans species of Candida in HIV-infected patients. Eur J Epidemiol. 9:1993;455-456
33. Redding S.W., Kirkpatrick W.R., Dib O., Fothergill A.W., Rinaldi M.G., Patterson T.F. The epidemiology of nonalbicans Candida in oropharyngeal candidiasis in HIV patients. Spec Care Dentist. 20:2000;178-181
34. Redding S.W. The role of yeasts other than Candida albicans in oropharyngeal candidiasis. Curr Opin Infect Dis. 14:2001;673-677
35. Schmidt-Westhausen A.M., Priepke F., Bergman F.J., Reichart P.A. Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med. 29:2000;336-341
36. Arribas J.R., Hernandez-Albujar S., Gonzalez-Garcia J.J., et al. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis. AIDS. 14:2000;979-985
37. Ceballos-Salobrena A., Gaitan-Cepeda L.A., Ceballos-Garcia L., Lezama-Del Valle D. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS. AIDS Patient Care STDS. 14:2000;627-635
38. Detels R., Tarwater P., Phair J.P., Margolick J., Riddler S.A., Munoz A. Multicenter AIDS Cohort Study. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS. 15:2001;347-355
39. Hube B. Candida albicans secreted aspartyl proteinases. Curr Top Med Micol. 7:1996;55-69
40. De Bernardis F., Arancia S., Morelli L., et al. Evidence that members of the secretory aspartyl proteinases gene family (SAP), in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis. 179:1999;201-208
41. De Bernardis F., Chiani P., Ciccozzi M., et al. Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect Immun. 64:1996;466-471
42. Hoods S., Bonington A., Evans J., Denning D. Reduction in oropharyngeal candidiasis following introduction of protease inhibitors. AIDS. 14:1998;447-448
43. Tappuni A.R., Fleming G.J.P. The effect of antiretroviral therapy on the prevalence of oral manifestations in HIV-infected patients: a UK study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 92:2001;623-628